Reported Saturday, Rhythm Pharmaceuticals Presents Phase 2 Data Showing Setmelanotide Achieves 3.06% Mean BMI Reduction And Clinically Meaningful Hyperphagia Improvements In Prader-Willi Syndrome Patients At ENDO 2026
Benzinga Newsdesk 4 months ago
News
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --
-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS